Equities

Navco Pharmaceuticals Inc

Navco Pharmaceuticals Inc

Actions
  • Price (CAD)0.035
  • Today's Change0.00 / 0.00%
  • Shares traded54.00k
  • 1 Year change-70.83%
  • Beta--
Data delayed at least 15 minutes, as of Apr 22 2024 16:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Navco Pharmaceuticals Inc. is a Canada-based company. The Company is engaged in developing and commercializing products to protect against viruses, bacteria, and infectious diseases. It manufactures and researches nanotechnology products and materials using Computerized Nano-meter Algorithms (CNA). The Company's pipeline of applications is tailored to defend against microorganisms such as viruses, bacteria, fungi, and genetic manipulation tools such as clustered regularly interspaced short palindromic repeats (CRISPR). Its target markets include human health and personal skin care, household and institutional products and veterinary health. It offers multiple main product lines, namely, an aerosol spray, hand sanitizer, hand cream, and nano BioGuard-Silver. It also offers sublingual strips (the MunoStrips) infused with immune-boosting compounds to help maintain immune function and help support the body’s metabolism.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-2.27m
  • Incorporated2018
  • Employees--
  • Location
    Navco Pharmaceuticals Inc1090 West Georgia Street, #600Vancouver V6E 3V7CanadaCAN
  • Phone+1 (778) 549-6714
  • Fax+1 (778) 549-6714
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Megola Inc0.000.001.95m5.00--0.1149----0.000.000.000.04270.00------0.00-26.730.00-32.61-------200.57----0.00-------100.00------
Toughbuilt Industries Inc122.39m-70.07m1.95m259.00--0.173--0.016-203.00-203.00310.5614.571.141.945.53346,033.30-65.18-74.66-158.32-170.5026.3927.44-57.25-52.750.2135--0.0788--36.0346.32-24.61--135.82--
Navco Pharmaceuticals Inc0.00-2.27m1.99m-----------0.4714-0.47140.00-0.00460.00-------648.75--------------0.5617-259.08----------------
Tantech Holdings Ltd73.05m4.13m2.90m99.000.16410.00580.72340.03983.413.4153.1696.960.398244.091.26540,306.101.93-4.212.18-5.1318.8716.974.83-11.667.82--0.0572---3.214.81136.15-3.98-42.49--
Mace Security International Inc9.01m-6.05m3.92m164.00--0.8309--0.4349-0.0676-0.06760.10090.05220.73171.297.09---49.17-10.95-64.84-13.6026.5037.09-67.20-10.180.572-17.740.3469---24.70-10.51-154.95---26.11--
CCA Industries Inc-136.56bn-136.56bn6.03m98.00--0.5572----------1.22----------2.09--3.03--60.34--1.850.982--0.0282---2.05-6.76-367.80--35.67--
Friday's Dog Holdings Inc553.40k-2.51m7.12m----1.22--12.87-0.0281-0.02810.00640.06960.07330.5094.89---33.20-147.73-35.28-163.81-10.09---452.73-12,928.6012.07--0.00-------4,548.37------
Stephan Co18.75m-12.28m8.13m95.00--0.6563--0.4338-2.22-2.293.392.210.89932.8423.25144,505.30-58.92-8.68-65.81-9.4318.5436.69-65.52-12.062.56--0.0055---9.07-5.30-3,763.61--38.38-12.94
Data as of Apr 22 2024. Currency figures normalised to Navco Pharmaceuticals Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.